#5364 LOW DOSE VALGANCICLOVIR AS A PRE-EMPTIVE THERAPY IS EFFECTIVE FOR CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

Abstract Background and Aims Pre-emptive therapy, screen for treat asymptomatic cytomegalovirus (CMV) viremia, is an important preventive strategy CMV disease in kidney transplant (KT) recipients. Oral valganciclovir the most commonly used as strategy. However, optimal dose treatment duration of remains elusive. Method We retrospectively evaluated efficacy toxicity low-dose oral (450 mg twice daily) pre-emptive therapy KT recipients who underwent between January 2015 December 2021. viral load was measured by polymerase chain reaction. with applied 2 weeks. Results 33 received (55 cases), 32 (97.0%) were seropositive except 1 patient had no related information. Thirty-two T-cell depleting agent, thymoglobulin induction immunosuppressive treatment. Treatment failure, defined a DNA more than or equal to 1000 copies/mL after weeks treatment, occurred 3 (5.45 %) patients. No developed during therapy. The median copies patients treated successfully 487.50 (311.24 – 826.25), whereas 4420.00 (2535.00 137450.00) undergone failure. Conclusion These results suggest that low can be preventing among low-level viremia. Further research needed replicate these findings larger samples assess long-term outcomes.